Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
The U.S. Department of Justice has closed its criminal investigation into Abbott Laboratories’ Michigan baby formula plant.
Authorities are pursuing civil penalties tied to alleged manufacturing failures that contributed to a national baby formula shortage.
The outcome clarifies a key regulatory risk and shifts the focus to civil, rather than criminal, enforcement.
Abbott Laboratories, ticker NYSE:ABT, now faces a clearer regulatory path as the criminal probe gives way to civil penalties. The stock most recently closed at $90.74, with the company showing a value score of 6 and multi year returns that have declined, including down 26.9% year to date and down 32.0% over the past year. For investors who have been tracking the regulatory overhang around its nutrition business, this news directly affects how they may think about risk and ongoing monitoring of the story.
Over the medium term, attention is likely to stay on how Abbott Laboratories manages compliance and quality control at its manufacturing facilities, given the previous impact on infant formula safety and supply. The shift to civil enforcement and defined penalties may lead investors to reassess the company’s risk profile, while ongoing performance of NYSE:ABT will depend on how effectively Abbott addresses operational and oversight expectations from regulators and customers.
Stay updated on the most important news stories for Abbott Laboratories by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Abbott Laboratories.
NYSE:ABT 1-Year Stock Price Chart
Quick Assessment
✅ Price vs Analyst Target: Abbott Laboratories trades at $90.74 versus an average analyst target of $116.54, around 28% below consensus.
✅ Simply Wall St Valuation: The stock is assessed as undervalued, trading 35.6% below an estimated fair value.
✅ Recent Momentum: The 30 day return is 6.0%, showing a recent rebound despite weaker multi year performance.
There’s only one way to know the right time to buy, sell or hold Abbott Laboratories. Head to Simply Wall St’s company report for the latest analysis of Abbott Laboratories’s Fair Value.
Key Considerations
📊 Closure of the criminal probe reduces a major regulatory overhang for Abbott Laboratories, with the focus now on quantifiable civil penalties.
📊 Monitor how management addresses quality controls at the Michigan plant, along with any future commentary on compliance spending or operational changes.
⚠️ Profit margins have fallen from 31.9% to 13.9% and the company carries a high level of debt, so balance sheet and profitability trends remain key risks.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Abbott Laboratories analysis. Alternatively, you can check out the community page for Abbott Laboratories to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ABT.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com